Mobile phone text message reminders of antipsychotic medication: is it time and who should receive them? A cross-sectional trust-wide survey of psychiatric inpatients

BMC Psychiatry

Eugenia Kravariti¹  Chike Ify Okocha²  Athanasios Prountzos¹  Daniel Hayes¹  Anthony Akenzua²  Christine Lewis³  Sook Kuan Wong¹  Katherine Bogart⁴ 

[1] Department of Psychosis Studies, Institute of Psychiatry at the Maudsley, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK;Oxleas NHS Foundation Trust, Pinewood House, Pinewood Place, Dartford, Kent DA2 7WG, UK;Bexley Crisis Resolution and Home Treatment Team, Erith Centre, Park Crescent, Erith DA8 3EE, UK;Wandsworth Psychological Therapies and Wellbeing, Springfield University Hospital, 61 Glenburnie Road, London SW17 7DJ, UK

关键词: Inpatients;    Mobile phone;    SMS;    Electronic reminders;    Medication adherence;    Antipsychotics;   

Others  :  1123827
DOI  :  10.1186/1471-244X-14-15

 received in 2013-09-04, accepted in 2014-01-18,  发布年份 2014

【 摘 要 】

Background

Poor adherence to antipsychotic medication is a widespread problem, and the largest predictor of relapse in patients with psychosis. Electronic reminders are increasingly used to improve medication adherence for a variety of medical conditions, but have received little attention in the context of psychotic disorders. We aimed to explore the feasibility and acceptability of including short message service (SMS) medication reminders in the aftercare plan of service users discharged from inpatient care on maintenance antipsychotic medication.

Methods

We conducted a cross-sectional, trust-wide survey in the inpatient units of the Oxleas National Health Service (NHS) Foundation Trust in the UK between June 29 and August 3, 2012. Using a self-report questionnaire and the Drug Attitude Inventory, we examined inpatient attitudes towards antipsychotic drugs, past adherence to antipsychotic medication, frequency of mobile phone ownership, and interest in receiving SMS medication reminders upon discharge from the ward. Predictors of a patient’s interest in receiving electronic reminders were examined using simple logistic regression models.

Results

Of 273 inpatients, 85 met eligibility criteria for the survey, showed decisional capacity, and agreed to participate. Of the 85 respondents, over a third (31-35%) admitted to have forgotten to take/collect their antipsychotic medication in the past, and approximately half (49%) to have intentionally skipped their antipsychotics or taken a smaller dose than prescribed. Male patients (55%), those with negative attitudes towards antipsychotics (40%), and those unsatisfied with the information they received on medication (35%) were approximately 3 to 4 times more likely to report past intentional poor adherence. The large majority of respondents (80-82%) reported having a mobile phone and knowing how to use SMS, and a smaller majority (59%) expressed an interest in receiving SMS medication reminders after discharge. No variable predicted a patient’s interest in receiving electronic reminders of antipsychotics.

Conclusions

Automatic SMS reminders of antipsychotic medication were acceptable to the majority of the survey respondents as an optional service offered upon discharge from inpatient care. Automatic electronic reminders deserve further investigation as a flexible, minimally invasive, cost-effective and broadly applicable tool that can potentially improve antipsychotic adherence and clinical outcomes.

【 授权许可】

   
2014 Bogart et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Rössler W, Salize HJ, van Os J, Riecher-Rössler A: Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005, 15(4):399-409.
• [2]Harwood RH, Sayer AA, Hirschfeld M: Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios. Bull World Health Organ 2004, 82(4):251-258.
• [3]World Health Organization: Pharmacological treatment of mental disorders in primary health care. http://whqlibdoc.who.int/publications/2009/9789241547697_eng.pdf webcite
• [4]Mangalore R, Knapp M: Cost of Schizophrenia in England. J Ment Health Policy Econ 2007, 109(1):23-41.
• [5]Noel JM: ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. Am J Health Syst Pharm 2007, 64(8):863-876.
• [6]Möller-Leimkühler A: Burden of relatives and predictors of burden. Baseline results from the Munich 5-year-followup study on relatives of first hospitalized patients with schizophrenia or depression. Eur Arch Psychiatry Clin Neurosci 2005, 255(4):223-231.
• [7]World Health Organization: Antipsychotic medications for psychotic disorders. http://www.who.int/mental_health/mhgap/evidence/resource/psychosis_q1.pdf webcite
• [8]Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI: Topiramate improves deficit symptoms in a patient with Schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2005, 24(5):290-294.
• [9]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223.
• [10]McCombs JS, Luo M, Johnstone BM, Shi L: The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000, 3(3):222-231.
• [11]Docherty JP, Grogg AL, Kozma C, Lasser R: Antipsychotic partial compliance: impact on clinical outcomes in schizophrenia. In Program and Abstracts of the 156th annual meeting of the American Psychiatric Association. San Francisco, CA: American Psychiatric Association; 2003. May 17–22. Abstract NR172
• [12]Nosé M, Barbui C, Tansella M: How often do patients with psychosis fail to adhere to treatment programmes? a systematic review. Psychol Med 2003, 33(7):1149-1160.
• [13]World Health Organization: Adherence to long-term therapies: evidence for action. http://www.who.int/chp/knowledge/publications/adherence_report/en/ webcite
• [14]Masand PS, Roca M, Turner MS, Kane JM: Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009, 11(4):147-154.
• [15]Llorca PM: Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008, 161(2):235-247.
• [16]Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiat Pract 2010, 16(1):34-45.
• [17]Nielsen RE, Lindström E, Nielsen J, Levander S: DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol 2012, 22(10):747-750.
• [18]Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M: Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizoph Res 2011, 130(1–3):176-181.
• [19]Deegan PE: The importance of personal medicine: a qualitative study of resilience in people with psychiatric disabilities. Scand J Public Health Suppl 2005, 66:29-35.
• [20]Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, Fleischhacker WW, et al.: Compliance in schizophrenia: psychopathology, side effects, and patients’ attitudes towards the illness and medication. J Clin Psychiatry 2004, 65(9):1211-1218.
• [21]Roe D, Goldblatt H, Baloush-Klienman V, Swarbrick M, Davidson L: Why and how people decide to stop taking prescribed psychiatric medication: exploring the subjective process of choice. Psychiatr Rehabil J 2009, 33(1):38-46.
• [22]Horne R, Price D, Cleland J, Costa R, Covey D, Gruffydd-Jones K, Haughney J, Henrichsen SH, Kaplan A, Langhammer A, et al.: Can asthma control be improved by understanding the patient’s perspective? BMC Pulm Med 2009, 7:8. BioMed Central Full Text
• [23]Clifford S, Barber N, Horne R: Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers. J Psychosom Res 2008, 64(1):41-46.
• [24]Vervloet M, Linn AJ, van Weert JC, De Bakker DH, Bouvy ML, van Dijk L: The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc 2012, 19(5):696-704.
• [25]Pijnenborg GH, Withaar FK, Brouwer WH, Timmerman ME, van den Bosch RJ, Evans JJ: The efficacy of SMS text messages to compensate for the effects of cognitive impairments in schizophrenia. Br J Clin Psychol 2010, 49(Pt 2):259-274.
• [26]Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL: Mobile Assessment and Treatment for Schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. Schizophr Bull 2012, 38(3):414-425.
• [27]Montes JM, Medina E, Gomez-Beneyto M, Maurino J: A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Res 2012, 200(2–3):89-95.
• [28]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington DC: USA; 2000.
• [29]Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC: A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry 2007, 64(8):966-974.
• [30]Sahm L, MacCurtain A, Hayden J, Roche C, Richards HL: Electronic reminders to improve medication adherence-are they acceptable to patients? Pharm World Sci 2009, 31(6):627-629.
• [31]Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13(1):177-183.
• [32]Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63(10):892-909.
• [33]McEvoy JP: The relationship between insight into psychosis and compliance with medications. In Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders. 2nd edition. Edited by Amador X, David A. New York: Oxford University Press; 2004:311-333.
• [34]Mitchell AJ, Selmes T: Why don’t patients take their medicine? Reasons and solutions in psychiatry. Advances Psych Treat 2007, 13:336-346.
• [35]Ofcom: A nation addicted to smartphones. http://consumers.ofcom.org.uk/2011/08/a-nation-addicted-to-smartphones/ webcite
• [36]Office for National Statistics: Percentage of Households with Selected Consumer Durables. UK; 2010. http://www.ons.gov.uk/ons/rel/family-spending/family-spending/family-spending-2011-edition/index.html webcite
• [37]Sanghara H, Kravariti E, Jakobsen H, Okocha C: Using short message services in mental health services: assessing feasibility. Mental Health Rev J 2010, 15(2):28-33.
• [38]Ben-Zeev D, Davis KE, Kaiser S, Krzsos I, Drake RE: Mobile technologies among people with serious mental illness: opportunities for future services. Adm Policy Ment Hlth 2013, 40(4):340-343.
• [39]Murali V, Oyebode F: Poverty, social inequality and mental health. Advances Psych Treat 2004, 10:216-224.
• [40]Alvarez-Jimenez M, Gleeson JF, Bendall S, Lederman R, Wadley G, Killackey E, McGorry PD: Internet-based interventions for psychosis: a sneak-peek into the future. Psychiat Clin N Am 2012, 35(3):735-747.
• [41]Sims H, Sanghara H, Hayes D, Wandiembe S, Finch M, Jakobsen H, Tsakanikos E, Okocha CI, Kravariti E: Text message reminders of appointments: a pilot intervention at four community mental health clinics in London. Psychiatr Serv 2012, 63(2):161-168.
• [42]Mutschler J, von Zitzewitz F, Rössler W, Grosshans M: Application of electronic diaries in patients with Schizophrenia and bipolar disorders. Psychiatr Danub 2012, 24(2):206-210.
• [43]Dolder CR, Lacro JP, Leckband S, Jeste DV: Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003, 23(4):389-399.
• [44]Loga-Zec S, Loga S: Antipsychotics and the quality of life of schizophrenic patients. Psychiatr Danub 2010, 22(4):495-497.
• [45]Eack SM, Newhill CE: Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull 2007, 33(5):1225-1237.
• [46]Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL: Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006, 32(4):724-742.